NCI-H522 Xenograft Model Service for NSCLC

The NCI-H522 xenograft model serves as a well-established lung adenocarcinoma platform distinguished by its wild-type EGFR background, making it particularly suited for evaluating therapeutic strategies outside the scope of canonical receptor tyrosine kinase inhibition. Alfa Cytology harnesses this authenticated adenocarcinoma lineage—supported by rigorous cell banking, standardized implantation protocols, and comprehensive endpoint analysis—to advance your preclinical oncology programs with reproducible, audit-ready pharmacodynamic data.

Overview of NCI-H522 Xenograft Model for NSCLC

The NCI-H522 cell line was established in 1982 by A.F. Gazdar, H.K. Oie, and J.D. Minna at the National Cancer Institute from a primary lung tumor specimen obtained from a male patient with lung adenocarcinoma. This line is classified as a bronchioloalveolar carcinoma subtype, originating from alveolar epithelium or bronchioles, and exhibits an epithelial morphology with adherent monolayer growth. Genetically, NCI-H522 harbors mutations in ^TP53 and deletions in the ^RB1 locus, contributing to genomic instability and uncontrolled proliferation. Notably, the line retains a wild-type ^EGFR and ^KRAS background, rendering it naturally resistant to EGFR-targeted tyrosine kinase inhibitors and positioning it as an ideal substrate for investigating alternative oncogenic drivers, epigenetic modulators, and DNA-damage response agents in a histologically faithful adenocarcinoma context.

Fig 1.Denature IP analysis showing the ALKBH5 PTM levels in the indicated lung cancer xenografts. (Yu, Fang, et al., 2025)

In immunodeficient hosts, NCI-H522 demonstrates reliable tumorigenicity with robust engraftment when 1×10⁷ cells are implanted subcutaneously, often with Matrigel support to enhance initial cell retention and vascularization. Tumors become palpable within 7–10 days and progress with consistent kinetics, maintaining histological features characteristic of lung adenocarcinoma including glandular architecture, mucin production, and expression of thyroid transcription factor-1 (TTF-1) and Napsin A. The model has been extensively utilized in high-throughput drug screening, resistance mechanism studies, and investigations into the tumor microenvironment, offering a versatile preclinical substrate for advancing therapeutic hypotheses in NSCLC.

Cell Line Information: NCI-H522

The following table presents the core biological, genetic, and operational characteristics of the NCI-H522 cell line to support informed experimental design and data interpretation.

Our Services

Alfa Cytology delivers an end-to-end NCI-H522 xenograft service encompassing authenticated cell banking, mycoplasma verification, tumor implantation, longitudinal monitoring, and multi-modal endpoint analysis. Our standardized workflows—refined across numerous adenocarcinoma studies—ensure consistent engraftment kinetics, reproducible tumor growth curves, and pharmacologically meaningful readouts that strengthen your preclinical development decisions.

Workflow of NCI-H522 Xenograft Model Construction

Construction of the NCI-H522 xenograft model at Alfa Cytology follows a regimented, IACUC-approved pipeline that prioritizes genetic authenticity, sterile technique, and reproducible tumor growth. Each operational phase is documented under GLP-aligned quality systems to ensure complete auditability from cell thaw to final dataset delivery.

1. Master Cell Bank Revival & Expansion: NCI-H522 cells are revived from authenticated, low-passage master stocks stored under liquid nitrogen and expanded in RPMI-1640 supplemented with 10% FBS. Each batch undergoes mycoplasma PCR screening, STR profiling confirmation, and viability assessment prior to harvest.
2. Pre-Implantation Cell Preparation: Cultures in logarithmic growth phase are dissociated with trypsin-EDTA, neutralized with complete medium, and pelleted by centrifugation at 200×g for 5 minutes. The pellet is washed twice with sterile PBS to eliminate serum traces, then resuspended in ice-cold PBS at a concentration of 1×10⁸ cells/mL for a final inoculum of 1×10⁷ cells per 100 μL injection volume.
3. Matrigel Mixing & Injection Preparation: High-concentration, phenol-red-free Matrigel is thawed at 4°C overnight and maintained on ice. The cell suspension is mixed 1:1 with cold Matrigel immediately before injection to promote cell retention, angiogenesis, and standardized engraftment kinetics. The mixture is kept on ice at all times to prevent premature polymerization.
4. Subcutaneous Tumor Implantation: Six- to eight-week-old female athymic nude mice are acclimatized for a minimum of seven days. Under aseptic conditions, 200 μL of the cell-Matrigel suspension is injected subcutaneously into the right flank using a 26-gauge needle. Mice are monitored daily for general health and injection-site integrity.
5. Tumor Establishment & Cohort Randomization: Tumors are monitored by palpation beginning on day 5 post-implantation. Once tumors become palpable and reach a mean volume of 80–120 mm³—typically 10–14 days after injection—mice are stratified by tumor size and randomized into vehicle control and treatment cohorts (n = 8–10 per group).
6. Dosing, Monitoring & Endpoint Analysis: Test agents are administered according to protocol-specified routes (PO, IP, IV, or SC) and schedules. Tumor dimensions and body weights are recorded twice weekly; tumor volume is calculated as (width)² × length / 2. Studies conclude at a humane endpoint (typically 2,000 mm³ or 21–28 days post-treatment), at which point tumors are excised, weighed, and allocated for histopathology (H&E), immunohistochemistry (TTF-1, Napsin A, Ki-67, CD31, TUNEL), and molecular profiling (qPCR, Western blot, RNA-seq).

Fig 2. NCI-H522 xenograft model construction workflow.

Case Study

In a recent preclinical evaluation, Alfa Cytology utilized the NCI-H522 subcutaneous xenograft to assess the efficacy of a novel epigenetic modulator in a wild-type EGFR lung adenocarcinoma setting. Following robust tumor engraftment in female athymic nude mice, animals were randomized into vehicle control and treatment arms (n = 8–10 per group) once mean tumor volume reached approximately 100 mm³. The test compound was administered via intraperitoneal injection on a daily schedule for 21 days. Longitudinal monitoring revealed a measurable reduction in tumor growth velocity in treated animals relative to vehicle controls, with the effect becoming apparent by the second week of dosing. At study termination, harvested tumors were subjected to comprehensive histopathological review and biomarker analysis, including TTF-1 and Napsin A staining to confirm adenocarcinoma lineage preservation, Ki-67 quantification to evaluate proliferative suppression, and TUNEL assay to assess apoptotic induction. Body weight records remained stable across all cohorts, indicating an acceptable tolerability profile. Complete pharmacodynamic datasets, including individual tumor growth trajectories and histology images, are available for disclosure under a confidentiality agreement.

Why Choose Alfa Cytology?

Engaging Alfa Cytology for your NCI-H522 xenograft program provides access to a purpose-built infrastructure optimized for lung adenocarcinoma preclinical research. Our service architecture combines scientific depth with operational agility to accelerate your compound evaluation timeline.

• Authenticated NCI-H522 master and working cell banks are maintained under liquid nitrogen with biannual STR confirmation and documented mycoplasma negativity, ensuring genetic stability across every study.
• Standardized implantation protocols with Matrigel support yield consistent tumor engraftment and predictable growth kinetics, enabling precise power calculations and efficient cohort sizing.
• Flexible study architectures accommodate single-agent, combination, dose-escalation, and epigenetic-targeting designs, with dosing routes and schedules tailored to your compound properties.
• On-site histopathology and IHC capabilities—including TTF-1, Napsin A, Ki-67, CD31, and TUNEL—deliver rapid turnaround without external vendor coordination or sample custody interruptions.
• Secure client data portals provide real-time visibility into tumor measurements, body weights, and study milestones, with automated notifications at predefined protocol checkpoints.
• Each engagement is supported by a dedicated scientific project manager who coordinates weekly progress reports, interim data presentations, and adaptive protocol amendments aligned with your evolving research priorities.

Contact Us

If your research pipeline focuses on lung adenocarcinoma—whether exploring epigenetic modulation, DNA-damage response targeting, or metabolic disruption in a wild-type EGFR context—Alfa Cytology offers the NCI-H522 xenograft expertise to advance your preclinical objectives with scientific rigor. Reach out to our scientific team today to discuss your study parameters, request a customized proposal, or arrange a consultation with our oncology model specialists. We are committed to converting your therapeutic hypothesis into robust, publication-ready preclinical evidence.

For research use only. Not intended for any clinical use.